Search products, brands, articles, and pages
Resources / Policy
Federal status, state-by-state bill tracking, regulatory developments, and analysis of proposed legislation. Maintained as a source for journalists, staffers, and researchers covering kratom policy.
FDA
No approved use
The FDA has issued import alerts and has, at multiple points, advised the DEA to schedule kratom. Kratom is not FDA-approved for any therapeutic indication and may not be marketed with therapeutic claims.
DEA
Not scheduled
A 2016 intent-to-schedule notice was withdrawn after public and legislative pushback. Kratom remains unscheduled federally. State-level scheduling varies (see state tracker below).
HHS
Review pending
HHS has reviewed scheduling recommendations but has not issued a final recommendation at this time. Kratom remains unscheduled pending HHS finalisation.
Banned statewide
KCPA enacted
Age-restricted
Local/county bans
This summary is a simplified view. For the canonical per-state status, including recent legislative movement, refer to the interactive state map linked above.
Kratom.com Editorial · Regulatory Affairs
Comparative legislative analysis, 2024 edition
The American Kratom Association (AKA) model KCPA text specifies age limits, labelling requirements, adulteration prohibitions, and alkaloid content caps. This brief compares the model to the enacted state versions and flags the 7-hydroxymitragynine cap variants that are most consequential for merchants.
FDA enforcement record, 2021–2024
A summary of FDA warning letters, import alerts, and public statements specifically targeting concentrated and synthetic 7-OH products (as distinct from whole-leaf kratom). Explains the regulatory bifurcation that kratom.com's product policy aligns with.
Internal methodology note
The inclusion criteria, data sources, and update cadence behind the state tracker. Notes where tracker data diverges from AKA and ACLU-reported figures and how those divergences are resolved.